Page 97 - MemoriaCIBER-2018ENG

cancer and the greater risk of infections reported.
• OSA is related to an increase in the aggressiveness of the cutaneous melanoma and a rise in high circulating levels of VCAM-1 which could indicate a contribution of OSA to tumorigenesis by means of the integrin-based adhesion pathway.
• Development of a simplified virtual sleep laboratory with integration of smart technology.
• A study with 70,469 patients treated with CPAP for sleep apnoea shows that the
Infectious Respiratory Diseases
Coordinator:
Antoni Torres Martí
Pneumonia Line
The PNEUMOCOPER line ended in December 2018. A report on the three-years’ life of the project was sent for evaluation by the ANECA, getting a mark of 12.5 out of 15. In the different sections valued the mark was always 4 or more points out of 5. Taking into account this very good evaluation we could say that the PNEUMOCOPER line was a considerable success. In 2018 two papers were published on two multi-centre clinical trials in the PNEUMOCOPER line: a) the REPROVE study published in Lancet Infectious Diseases (Torres A, et al. Lancet Infect Dis. 2018 Mar;18(3):285-295) and b) the CIGMA study, published in Intensive Care Medicine (Welte
T, et al. Intensive Care Med. 2018 Apr;44(4):438- 448). Lastly the new proposal for the pneumonia line entitled PREDITNEU was completed and delivered, its coordinators being: Carmen Ardanuy, Laia Fernández-Barat and Miquel Ferrer. The external valuation of the new line was 13 out of 15. This is a reflection of the scientific strength and networking of all the groups taking part in these lines.
treatment is associated with a reduction in mortality in men, but not in women.
• Prominent participation (chairman) in the preparation of an official clinical practice guide of the American Thoracic Society (ATS) (Evaluation and handling of the obesity- hypoventilation syndrome).
Tuberculosis Line
In 2018 the work done by the research groups in the Line focussed on three main approaches to their action:
• Prevention: design, evaluation and development of: new candidates for
vaccines (including MTBVAC), multivalent vaccines, hyper-attenuated vaccines for
use in immune-suppressed patients. New prophylactic strategies for preventing infection by tuberculosis, active disease and the transmission of high-risk tuberculosis integrating the sequencing of whole genomes and specific PCRs of strains.
• Diagnosis: study of tuberculosis lesions obtained by surgery to seek biomarkers correlating with the pathology. Development and assessment of: new molecular and immune tests for latent tuberculosis infection, new point-of-care techniques for fast diagnosis intended for countries with low income and high rates of tuberculosis, and new tools in molecular epidemiology.
• Treatment: basic and clinical development of new antituberculosis drugs: evaluation of new therapeutic strategies intended for the host.
There were 32 publications in 2018.
97
CIBERES | ANNUAL REPORT 2018